Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine

Expert Review of Anticancer Therapy · Published 2026-06-30 · DOI 10.1080/14737140.2026.2695214

Free full text

Authors (17)

Chiara Mercinelli, Fabrizio Di Costanzo, Christoph Oing, Gualtiero Guandalini, Brigida Anna Maiorano, Enrico Sammarco, Alessia Salfi, Debora Serafin, Valentina Tateo, Antonio Cigliola, Michela Piacentini, Giovanni Luigi Pastorino, Luca Galli, Vincenza Conteduca, Luigi Formisano, Pasquale Rescigno, Andrea Necchi

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Mercinelli, C., Costanzo, F., Oing, C., et al. (2026). Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine. Expert Review of Anticancer Therapy. https://doi.org/10.1080/14737140.2026.2695214

Related articles

• Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer · Future Oncology · 2026 · Cites or is cited by this article
• The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma · Expert Review of Anticancer Therapy · 2026 · Same journal
• Emerging immune checkpoint inhibitor strategies in cervical cancer: a scoping review of ongoing clinical trials · Expert Review of Anticancer Therapy · 2026 · Same journal
• Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection · Expert Review of Anticancer Therapy · 2026 · Same journal
• The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis · Expert Review of Anticancer Therapy · 2026 · Same journal
• Angiosarcoma: adaptive designs leveraging vascular biology and antiangiogenic repurposing · Expert Review of Anticancer Therapy · 2026 · Same journal
• Quantitative and qualitative fecal immunochemical tests for colorectal cancer screening in Kazakhstan: a comparative study · Expert Review of Anticancer Therapy · 2026 · Same journal
• Frailty is not ECOG: why performance status alone is no longer enough in anticancer therapy · Expert Review of Anticancer Therapy · 2026 · Same journal
• Can we consider stopping hepatocellular carcinoma surveillance in low-risk patients with hepatitis B? · Expert Review of Anticancer Therapy · 2026 · Same journal
• Association of neoadjuvant chemotherapy with outcomes in patients with elevated preoperative Ca 19–9 undergoing pancreatic ductal adenocarcinoma resection · Expert Review of Anticancer Therapy · 2026 · Same journal